Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
Identifieur interne : 000415 ( Main/Exploration ); précédent : 000414; suivant : 000416Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
Auteurs : Andrei Shustov [États-Unis] ; Bertrand Coiffier [France] ; Steven Horwitz [États-Unis] ; Lubomir Sokol [États-Unis] ; Barbara Pro [États-Unis] ; Julie Wolfson [États-Unis] ; Barbara Balser [États-Unis] ; Robin Eisch [États-Unis] ; Leslie Popplewell [États-Unis] ; H Miles Prince [Australie] ; Steven L. Allen [États-Unis] ; Richard Piekarz [États-Unis] ; Susan Bates [États-Unis]Source :
- Leukemia & lymphoma [ 1029-2403 ] ; 2017.
Abstract
Peripheral T-cell lymphomas (PTCLs) are a rare group of lymphoid neoplasms with high relapse rates after initial therapy and poor prognosis. Most patients are aged ≥60 years and are often not candidates for aggressive salvage therapies. Romidepsin, a potent class I histone deacetylase inhibitor, has shown significant single-agent activity in relapsed/refractory PTCL. We evaluated the efficacy and tolerability of romidepsin in elderly patients in this setting. Ninety-five patients aged ≥60 years were identified from 2 prospective phase 2 registration trials of romidepsin, and comparative analyses were performed with younger patients from these trials. Response rates, progression-free survival, and overall survival were not statistically different for younger vs older patients. The toxicity profile in older and younger patients was similar in both trials. Romidepsin demonstrated similar efficacy and tolerability in younger and older patients and presents an attractive treatment option for relapsed/refractory PTCL regardless of age.
DOI: 10.1080/10428194.2017.1295143
PubMed: 28264616
Affiliations:
- Australie, France, États-Unis
- Californie, Floride, Maryland, Massachusetts, Pennsylvanie, Washington (État), État de New York
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000327
- to stream PubMed, to step Curation: 000325
- to stream PubMed, to step Checkpoint: 000325
- to stream Ncbi, to step Merge: 004421
- to stream Ncbi, to step Curation: 004421
- to stream Ncbi, to step Checkpoint: 004421
- to stream Main, to step Merge: 000410
- to stream Main, to step Curation: 000415
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.</title><author><name sortKey="Shustov, Andrei" sort="Shustov, Andrei" uniqKey="Shustov A" first="Andrei" last="Shustov">Andrei Shustov</name><affiliation wicri:level="2"><nlm:affiliation>a Department of Hematology , University of Washington Medical Center , Seattle , WA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Department of Hematology , University of Washington Medical Center , Seattle , WA </wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name><affiliation wicri:level="1"><nlm:affiliation>b Department of Hematology , Hospices Civils de Lyon , Lyon , France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>b Department of Hematology , Hospices Civils de Lyon , Lyon </wicri:regionArea><wicri:noRegion>Lyon </wicri:noRegion><wicri:noRegion>Lyon </wicri:noRegion></affiliation></author><author><name sortKey="Horwitz, Steven" sort="Horwitz, Steven" uniqKey="Horwitz S" first="Steven" last="Horwitz">Steven Horwitz</name><affiliation wicri:level="2"><nlm:affiliation>c Department of Oncology , Memorial Sloan Kettering Cancer Center , New York , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>c Department of Oncology , Memorial Sloan Kettering Cancer Center , New York , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Sokol, Lubomir" sort="Sokol, Lubomir" uniqKey="Sokol L" first="Lubomir" last="Sokol">Lubomir Sokol</name><affiliation wicri:level="2"><nlm:affiliation>d Department of Hematology , Moffitt Cancer Center , Tampa , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>d Department of Hematology , Moffitt Cancer Center , Tampa , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Pro, Barbara" sort="Pro, Barbara" uniqKey="Pro B" first="Barbara" last="Pro">Barbara Pro</name><affiliation wicri:level="2"><nlm:affiliation>e Department of Hematology/Oncology , Kimmel Cancer Center, Thomas Jefferson University , Philadelphia , PA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>e Department of Hematology/Oncology , Kimmel Cancer Center, Thomas Jefferson University , Philadelphia , PA </wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Wolfson, Julie" sort="Wolfson, Julie" uniqKey="Wolfson J" first="Julie" last="Wolfson">Julie Wolfson</name><affiliation wicri:level="2"><nlm:affiliation>f Veristat, LLC , Southborough , MA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>f Veristat, LLC , Southborough , MA </wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Balser, Barbara" sort="Balser, Barbara" uniqKey="Balser B" first="Barbara" last="Balser">Barbara Balser</name><affiliation wicri:level="2"><nlm:affiliation>f Veristat, LLC , Southborough , MA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>f Veristat, LLC , Southborough , MA </wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Eisch, Robin" sort="Eisch, Robin" uniqKey="Eisch R" first="Robin" last="Eisch">Robin Eisch</name><affiliation wicri:level="2"><nlm:affiliation>g Department of Investigational Therapeutics , National Cancer Institute , Bethesda , MD , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>g Department of Investigational Therapeutics , National Cancer Institute , Bethesda , MD </wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Popplewell, Leslie" sort="Popplewell, Leslie" uniqKey="Popplewell L" first="Leslie" last="Popplewell">Leslie Popplewell</name><affiliation wicri:level="2"><nlm:affiliation>h Department of Hematology/Oncology , City of Hope Medical Center-Oncology , Duarte , CA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>h Department of Hematology/Oncology , City of Hope Medical Center-Oncology , Duarte , CA </wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Prince, H Miles" sort="Prince, H Miles" uniqKey="Prince H" first="H Miles" last="Prince">H Miles Prince</name><affiliation wicri:level="1"><nlm:affiliation>i Department of Hematology , Peter MacCallum Cancer Centre and University of Melbourne , Melbourne , Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>i Department of Hematology , Peter MacCallum Cancer Centre and University of Melbourne , Melbourne </wicri:regionArea><wicri:noRegion>Melbourne </wicri:noRegion></affiliation></author><author><name sortKey="Allen, Steven L" sort="Allen, Steven L" uniqKey="Allen S" first="Steven L" last="Allen">Steven L. Allen</name><affiliation wicri:level="2"><nlm:affiliation>j Department of Hematology , Hofstra North Shore-LIJ School of Medicine and Monter Cancer Center , Lake Success , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>j Department of Hematology , Hofstra North Shore-LIJ School of Medicine and Monter Cancer Center , Lake Success , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Piekarz, Richard" sort="Piekarz, Richard" uniqKey="Piekarz R" first="Richard" last="Piekarz">Richard Piekarz</name><affiliation wicri:level="2"><nlm:affiliation>g Department of Investigational Therapeutics , National Cancer Institute , Bethesda , MD , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>g Department of Investigational Therapeutics , National Cancer Institute , Bethesda , MD </wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bates, Susan" sort="Bates, Susan" uniqKey="Bates S" first="Susan" last="Bates">Susan Bates</name><affiliation wicri:level="2"><nlm:affiliation>k Department of Hematology/Oncology , Columbia University Medical Center , New York , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>k Department of Hematology/Oncology , Columbia University Medical Center , New York , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28264616</idno><idno type="pmid">28264616</idno><idno type="doi">10.1080/10428194.2017.1295143</idno><idno type="wicri:Area/PubMed/Corpus">000327</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000327</idno><idno type="wicri:Area/PubMed/Curation">000325</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000325</idno><idno type="wicri:Area/PubMed/Checkpoint">000325</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000325</idno><idno type="wicri:Area/Ncbi/Merge">004421</idno><idno type="wicri:Area/Ncbi/Curation">004421</idno><idno type="wicri:Area/Ncbi/Checkpoint">004421</idno><idno type="wicri:Area/Main/Merge">000410</idno><idno type="wicri:Area/Main/Curation">000415</idno><idno type="wicri:Area/Main/Exploration">000415</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.</title><author><name sortKey="Shustov, Andrei" sort="Shustov, Andrei" uniqKey="Shustov A" first="Andrei" last="Shustov">Andrei Shustov</name><affiliation wicri:level="2"><nlm:affiliation>a Department of Hematology , University of Washington Medical Center , Seattle , WA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>a Department of Hematology , University of Washington Medical Center , Seattle , WA </wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name><affiliation wicri:level="1"><nlm:affiliation>b Department of Hematology , Hospices Civils de Lyon , Lyon , France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>b Department of Hematology , Hospices Civils de Lyon , Lyon </wicri:regionArea><wicri:noRegion>Lyon </wicri:noRegion><wicri:noRegion>Lyon </wicri:noRegion></affiliation></author><author><name sortKey="Horwitz, Steven" sort="Horwitz, Steven" uniqKey="Horwitz S" first="Steven" last="Horwitz">Steven Horwitz</name><affiliation wicri:level="2"><nlm:affiliation>c Department of Oncology , Memorial Sloan Kettering Cancer Center , New York , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>c Department of Oncology , Memorial Sloan Kettering Cancer Center , New York , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Sokol, Lubomir" sort="Sokol, Lubomir" uniqKey="Sokol L" first="Lubomir" last="Sokol">Lubomir Sokol</name><affiliation wicri:level="2"><nlm:affiliation>d Department of Hematology , Moffitt Cancer Center , Tampa , FL , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>d Department of Hematology , Moffitt Cancer Center , Tampa , FL </wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Pro, Barbara" sort="Pro, Barbara" uniqKey="Pro B" first="Barbara" last="Pro">Barbara Pro</name><affiliation wicri:level="2"><nlm:affiliation>e Department of Hematology/Oncology , Kimmel Cancer Center, Thomas Jefferson University , Philadelphia , PA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>e Department of Hematology/Oncology , Kimmel Cancer Center, Thomas Jefferson University , Philadelphia , PA </wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Wolfson, Julie" sort="Wolfson, Julie" uniqKey="Wolfson J" first="Julie" last="Wolfson">Julie Wolfson</name><affiliation wicri:level="2"><nlm:affiliation>f Veristat, LLC , Southborough , MA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>f Veristat, LLC , Southborough , MA </wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Balser, Barbara" sort="Balser, Barbara" uniqKey="Balser B" first="Barbara" last="Balser">Barbara Balser</name><affiliation wicri:level="2"><nlm:affiliation>f Veristat, LLC , Southborough , MA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>f Veristat, LLC , Southborough , MA </wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Eisch, Robin" sort="Eisch, Robin" uniqKey="Eisch R" first="Robin" last="Eisch">Robin Eisch</name><affiliation wicri:level="2"><nlm:affiliation>g Department of Investigational Therapeutics , National Cancer Institute , Bethesda , MD , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>g Department of Investigational Therapeutics , National Cancer Institute , Bethesda , MD </wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Popplewell, Leslie" sort="Popplewell, Leslie" uniqKey="Popplewell L" first="Leslie" last="Popplewell">Leslie Popplewell</name><affiliation wicri:level="2"><nlm:affiliation>h Department of Hematology/Oncology , City of Hope Medical Center-Oncology , Duarte , CA , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>h Department of Hematology/Oncology , City of Hope Medical Center-Oncology , Duarte , CA </wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Prince, H Miles" sort="Prince, H Miles" uniqKey="Prince H" first="H Miles" last="Prince">H Miles Prince</name><affiliation wicri:level="1"><nlm:affiliation>i Department of Hematology , Peter MacCallum Cancer Centre and University of Melbourne , Melbourne , Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>i Department of Hematology , Peter MacCallum Cancer Centre and University of Melbourne , Melbourne </wicri:regionArea><wicri:noRegion>Melbourne </wicri:noRegion></affiliation></author><author><name sortKey="Allen, Steven L" sort="Allen, Steven L" uniqKey="Allen S" first="Steven L" last="Allen">Steven L. Allen</name><affiliation wicri:level="2"><nlm:affiliation>j Department of Hematology , Hofstra North Shore-LIJ School of Medicine and Monter Cancer Center , Lake Success , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>j Department of Hematology , Hofstra North Shore-LIJ School of Medicine and Monter Cancer Center , Lake Success , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Piekarz, Richard" sort="Piekarz, Richard" uniqKey="Piekarz R" first="Richard" last="Piekarz">Richard Piekarz</name><affiliation wicri:level="2"><nlm:affiliation>g Department of Investigational Therapeutics , National Cancer Institute , Bethesda , MD , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>g Department of Investigational Therapeutics , National Cancer Institute , Bethesda , MD </wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bates, Susan" sort="Bates, Susan" uniqKey="Bates S" first="Susan" last="Bates">Susan Bates</name><affiliation wicri:level="2"><nlm:affiliation>k Department of Hematology/Oncology , Columbia University Medical Center , New York , NY , USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>k Department of Hematology/Oncology , Columbia University Medical Center , New York , NY </wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j">Leukemia & lymphoma</title><idno type="eISSN">1029-2403</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Peripheral T-cell lymphomas (PTCLs) are a rare group of lymphoid neoplasms with high relapse rates after initial therapy and poor prognosis. Most patients are aged ≥60 years and are often not candidates for aggressive salvage therapies. Romidepsin, a potent class I histone deacetylase inhibitor, has shown significant single-agent activity in relapsed/refractory PTCL. We evaluated the efficacy and tolerability of romidepsin in elderly patients in this setting. Ninety-five patients aged ≥60 years were identified from 2 prospective phase 2 registration trials of romidepsin, and comparative analyses were performed with younger patients from these trials. Response rates, progression-free survival, and overall survival were not statistically different for younger vs older patients. The toxicity profile in older and younger patients was similar in both trials. Romidepsin demonstrated similar efficacy and tolerability in younger and older patients and presents an attractive treatment option for relapsed/refractory PTCL regardless of age.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>États-Unis</li></country><region><li>Californie</li><li>Floride</li><li>Maryland</li><li>Massachusetts</li><li>Pennsylvanie</li><li>Washington (État)</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Washington (État)"><name sortKey="Shustov, Andrei" sort="Shustov, Andrei" uniqKey="Shustov A" first="Andrei" last="Shustov">Andrei Shustov</name></region><name sortKey="Allen, Steven L" sort="Allen, Steven L" uniqKey="Allen S" first="Steven L" last="Allen">Steven L. Allen</name><name sortKey="Balser, Barbara" sort="Balser, Barbara" uniqKey="Balser B" first="Barbara" last="Balser">Barbara Balser</name><name sortKey="Bates, Susan" sort="Bates, Susan" uniqKey="Bates S" first="Susan" last="Bates">Susan Bates</name><name sortKey="Eisch, Robin" sort="Eisch, Robin" uniqKey="Eisch R" first="Robin" last="Eisch">Robin Eisch</name><name sortKey="Horwitz, Steven" sort="Horwitz, Steven" uniqKey="Horwitz S" first="Steven" last="Horwitz">Steven Horwitz</name><name sortKey="Piekarz, Richard" sort="Piekarz, Richard" uniqKey="Piekarz R" first="Richard" last="Piekarz">Richard Piekarz</name><name sortKey="Popplewell, Leslie" sort="Popplewell, Leslie" uniqKey="Popplewell L" first="Leslie" last="Popplewell">Leslie Popplewell</name><name sortKey="Pro, Barbara" sort="Pro, Barbara" uniqKey="Pro B" first="Barbara" last="Pro">Barbara Pro</name><name sortKey="Sokol, Lubomir" sort="Sokol, Lubomir" uniqKey="Sokol L" first="Lubomir" last="Sokol">Lubomir Sokol</name><name sortKey="Wolfson, Julie" sort="Wolfson, Julie" uniqKey="Wolfson J" first="Julie" last="Wolfson">Julie Wolfson</name></country><country name="France"><noRegion><name sortKey="Coiffier, Bertrand" sort="Coiffier, Bertrand" uniqKey="Coiffier B" first="Bertrand" last="Coiffier">Bertrand Coiffier</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Prince, H Miles" sort="Prince, H Miles" uniqKey="Prince H" first="H Miles" last="Prince">H Miles Prince</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000415 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000415 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28264616
|texte= Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28264616" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |